|Day Low/High||5.98 / 6.13|
|52 Wk Low/High||5.83 / 11.00|
Vertex Pharmaceuticals, FibroGen and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading trading on July 19.
We brought a new name into the portfolio last week as the Fed's comments helped lift the market.
We made no trades during the holiday-shortened week, but added to our natural hedge today.
Exelixis, Omeros and Inovio Pharmaceuticals were among the biotech movers in premarket trading on July 10.
Inovio dMAb® product induces complete protection against lethal challenge with influenza A & B viruses in published preclinical study
We added a name to the portfolio's Bullpen as a whirlwind quarter came to an end.
We exited 2 positions and took some profits during a busy week for the portfolio.
We initiated a new position and made several other trades during a week of twists and turns.
We initiated 2 new positions in a week dominated by political events.
We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.
Jim Cramer takes a closer look at Inovio Pharmaceuticals, a small biotech developing DNA-based immunotherapies to treat cancer.
Jim Cramer says the story is less about Comey vs. Trump than it is about Nvidia vs. Nordstrom.
NewLink Genetics, Inovio Pharmaceuticals and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.
FDA removes clinical hold on phase 3; Inovio to immediately begin recruiting subjects
Zika DNA vaccine may protect against sexual transmission
Phase 1b/2 clinical trial to evaluate combination of Inovio's T cell immunotherapy INO-5401 and Genentech's PD-L1 checkpoint inhibitor atezolizumab
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
Amongst highest levels of immune responses ever demonstrated in an HIV vaccine human study